- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Bluebird bio Inc (BLUE)
Bluebird bio Inc stock price live, this page displays NASDAQ BLUE stock exchange data. View the BLUE premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Bluebird bio Inc real time stock price chart below.
What Is the Bluebird bio Inc Stock Price Today?
The Bluebird bio Inc stock price today is 4.9800.
What Is the Stock Symbol for Bluebird bio Inc?
The stock symbol for Bluebird bio Inc is "BLUE."
What Stock Exchange Does Bluebird bio Inc Trade On?
Bluebird bio Inc is listed and trades on the NASDAQ stock exchange.
Is Bluebird bio Inc a Good Stock to Buy?
Determining whether Bluebird bio Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the BLUE quote. (ISIN: US09609G2093)
What Is the Bluebird bio Inc Stock Price Today?
The Bluebird bio Inc stock price today is 4.9800.
What Is the Stock Symbol for Bluebird bio Inc?
The stock symbol for Bluebird bio Inc is "BLUE."
What Stock Exchange Does Bluebird bio Inc Trade On?
Bluebird bio Inc is listed and trades on the NASDAQ stock exchange.
Is Bluebird bio Inc a Good Stock to Buy?
Determining whether Bluebird bio Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the BLUE quote. (ISIN: US09609G2093)
4.9800
+1.6700(+50.45%)
Closed·
Pre Market
4.9600-0.0200(-0.40%)
·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.9500
4.9900
52 wk Range
3.2000
28.6000
BLUE Scorecard
Full Analysis
Operates with a significant debt burden
Unusual trading volume
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.95004.9900
52 wk Range
3.200028.6000
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
BLUE Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceAnalysts Sentiment
Neutral
Price Target
7.0000
Upside
+40.56%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales growth in the current year
Bluebird Company Profile
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for curative severe genetic diseases in the United States. The company’s product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; LYFGENIA (lovotibeglogene autotemcel) for the treatment of sickle cell disease (SCD) and a history of vaso-occlusive events; and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. Its clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.
Bluebird bio Inc SWOT Analysis
Gene Therapy Pionee | Explore bluebird bio's innovative treatments for severe genetic diseases, including its lead product Lyfgenia for sickle cell disease |
Financial Tightrope | Delve into bluebird's financial challenges, with a limited runway extending into Q1 2025 and efforts to reach cash flow break-even by H2 2025 |
Market Potential | Analyst price targets range from $2 to $40, reflecting diverse views on bluebird's growth prospects in the expanding gene therapy market |
Launch Execution | Learn about bluebird's progress in patient starts across treatments and the critical importance of successful product launches for future success |
Bluebird bio Inc Earnings Call Summary for Q3/2024
- Patient starts more than doubled to 57 in Q3; Q4 revenue expected to rebound to $25M+ despite Q3 decline to $10.6M
- Cash flow breakeven targeted for H2 2025, contingent on securing additional funding; 20% reduction in operating expenses planned
- Over 50% of U.S. states confirm coverage for LYFGENIA; manufacturing capacity to double by 2026 to meet demand
- Reverse stock split proposed to regain NASDAQ compliance; shareholder meeting scheduled for December 4
- Company managing cash gap anticipated in Q2 2025 through contract renegotiations and partnerships
Last Updated: 15-11-2024, 02:28 am
Read Full TranscriptCompare BLUE to Peers and Sector
Metrics to compare | BLUE | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBLUEPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.2x | −2.1x | −0.5x | |
PEG Ratio | −0.01 | −0.01 | 0.00 | |
Price/Book | −1.5x | 1.2x | 2.6x | |
Price / LTM Sales | 0.6x | 17.6x | 2.9x | |
Upside (Analyst Target) | 61.3% | 557.4% | 51.4% | |
Fair Value Upside | Unlock | 7.6% | 9.5% | Unlock |
Analyst Ratings
1 Buy
4 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Neutral
Analysts 12-Month Price Target:
Average 7.0000
(+40.56% Upside)
Earnings
Latest Release
Feb 25, 2025
EPS / Forecast
-2.95 / -0.2944
Revenue / Forecast
38.52M / 26.06M
FAQ
What Is the Bluebird (BLUE) Stock Price Today?
The Bluebird stock price today is 4.98.
What Stock Exchange Does Bluebird Trade On?
Bluebird is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Bluebird?
The stock symbol for Bluebird is "BLUE."
What Is the Bluebird Market Cap?
As of today, Bluebird market cap is 48.75M.
What Is Bluebird's Earnings Per Share (TTM)?
The Bluebird EPS (TTM) is -24.84.
From a Technical Analysis Perspective, Is BLUE a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.